Key Takeaway: Sanofi has released information regarding the total number of voting rights and shares as of February 28, 2026. The registered share capital amounts to €2,424,365,088, with a total of 1,219,502,262 issued shares. The number of real voting rights, excluding treasury shares, is reported as 1,337,158,714, while the theoretical number of voting rights, including treasury shares, stands at 1,353,591,491. This disclosure is made in accordance with French commercial regulations and is available on Sanofi's investor website.
Price reaction · baseline $43.94 (2026-03-11 close) · hit after-hours · clean, no other SNY news in the window
day 0 close · peak
-0.7%
Market Sentiment Analysis
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+11%
120-day peak, hindsight
Typical move
1.8%
average across 15 past catalysts
Lead asset
teplizumab/mL
Phase 2 · Diabetes Mellitus, Type 1
Full Press Release Details
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority)
a French société anonyme with a registered share capital of €2,424,365,088
Registered office : 46, avenue de la Grande Armée - 75017 Paris - France
Registered at the Paris Commercial and Companies Registry under number 395 030 844
Date
Total number of issued shares
Number of real voting rights (excluding treasury shares)
Theoretical number of voting rights (including treasury shares)*
28 February 2026
1,219,502,262
1,337,158,714
1,353,591,491
* Pursuant to Article 223-11 of the Règlement général de l’Autorité des Marchés Financiers.
This information is also available on the internet website of sanofi: